BeOne Medicines AG (BEIGF)

Market Cap	39.16B +65.4%
Revenue (ttm)	4.97B +50.4%
Net Income	68.55M
EPS	0.58
Shares Out	n/a
PE Ratio	571.32
Forward PE	66.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,000
Average Volume	5,628
Open	24.92
Previous Close	24.92
Day's Range	24.92 - 24.92
52-Week Range	13.68 - 24.92
Beta	0.47
RSI	63.58
Earnings Date	Apr 15, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.